Research programme: toll-like receptor 4 modulators - GlaxoSmithKlineAlternative Names: CRX 527; TLR 4 modulators - GlaxoSmithKline; Toll-like receptor 4 modulators research programme - GlaxoSmithKline
Latest Information Update: 25 May 2007
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action Toll-like receptor 4 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 09 Sep 2003 Preclinical trials in Immunological disorders in USA (unspecified route)